BBC vs. ARKG
Compare and contrast key facts about Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
BBC and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BBC is a passively managed fund by Virtus Investment Partners that tracks the performance of the LifeSci Biotechnology Clinical Trials Index. It was launched on Dec 16, 2014. ARKG is an actively managed fund by ARK Investment Management. It was launched on Oct 31, 2014.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BBC or ARKG.
Correlation
The correlation between BBC and ARKG is 0.81, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
BBC vs. ARKG - Performance Comparison
Key characteristics
BBC:
0.14
ARKG:
-0.74
BBC:
0.45
ARKG:
-0.93
BBC:
1.05
ARKG:
0.90
BBC:
0.08
ARKG:
-0.37
BBC:
0.43
ARKG:
-1.25
BBC:
11.69%
ARKG:
23.77%
BBC:
35.11%
ARKG:
40.40%
BBC:
-72.73%
ARKG:
-80.10%
BBC:
-60.72%
ARKG:
-79.47%
Returns By Period
In the year-to-date period, BBC achieves a -0.90% return, which is significantly higher than ARKG's -30.05% return. Over the past 10 years, BBC has underperformed ARKG with an annualized return of -1.30%, while ARKG has yielded a comparatively higher 1.40% annualized return.
BBC
-0.90%
-8.00%
-3.00%
8.96%
-8.39%
-1.30%
ARKG
-30.05%
-1.33%
-5.56%
-26.21%
-7.67%
1.40%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BBC vs. ARKG - Expense Ratio Comparison
BBC has a 0.79% expense ratio, which is higher than ARKG's 0.75% expense ratio.
Risk-Adjusted Performance
BBC vs. ARKG - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BBC vs. ARKG - Dividend Comparison
Neither BBC nor ARKG has paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
BBC Virtus LifeSci Biotech Clinical Trials ETF | 0.00% | 0.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.04% | 0.00% | 0.51% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 1.94% | 1.34% | 0.00% | 0.00% |
Drawdowns
BBC vs. ARKG - Drawdown Comparison
The maximum BBC drawdown since its inception was -72.73%, smaller than the maximum ARKG drawdown of -80.10%. Use the drawdown chart below to compare losses from any high point for BBC and ARKG. For additional features, visit the drawdowns tool.
Volatility
BBC vs. ARKG - Volatility Comparison
The current volatility for Virtus LifeSci Biotech Clinical Trials ETF (BBC) is 11.19%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 14.12%. This indicates that BBC experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.